Abstract:A repeat expansion mutation in the C9orf72 gene is the leading known genetic cause of FTD and ALS. The C9orf72- ALS/FTD field has been plagued by a lack of reliable tools to monitor this genomic locus and its RNA and protein products. We have validated assays that quantify C9orf72 pathobiology at the DNA, RNA and protein levels using knock-out human iPSC lines as controls. Here we show that single-molecule sequencing can accurately measure the repeat expansion and faithfully report on changes to the C9orf72 locus in what has been a traditionally hard to sequence genomic region. This is of particular value to sizing and phasing the repeat expansion and determining changes to the gene locus after gene editing. We developed ddPCR assays to quantify two major C9orf72 transcript variants, which we validated by selective excision of their distinct transcriptional start sites. Using validated knock-out human iPSC lines, we validated 4 commercially available antibodies (of 9 tested) that were specific for C9orf72 protein quantification by Western blot, but none were specific for immunocytochemistry. We tested 15 combinations of antibodies against dipeptide repeat proteins (DPRs) across 66 concentrations using MSD immunoassay, and found two (against poly-GA and poly-GP) that yielded a 1.5-fold or greater signal increase in patient iPSC-motor neurons compared to knock-out control, and validated them in human postmortem and transgenic mouse brain tissue. Our validated DNA, RNA and protein assays are applicable to discovery research as well as clinical trials.

What problem does this paper attempt to address?

This paper attempts to solve the key problems encountered in the research of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) related to the C9orf72 gene. Specifically, the paper mainly focuses on the following aspects: 1. **Accurate measurement of C9orf72 gene repeat expansions**: - Current methods for clinical diagnosis of C9orf72 gene repeat expansions (such as long - distance PCR and Southern blotting) lack precision, especially when measuring larger repeat expansions. These methods require a large amount of DNA input and are not effective in detecting rare or mixed - size repeats. - Researchers use single - molecule sequencing technology, which can measure the length of repeat expansions in the C9orf72 gene more accurately, and can even measure thousands of repeat units. This method requires less DNA input and is more accurate than traditional GS/RP - PCR. 2. **Evaluating the effects of CRISPR gene editing**: - Using single - molecule sequencing technology, researchers can conduct more detailed analysis of cells after CRISPR gene editing, especially can distinguish the editing results on different alleles. This helps to determine whether the editing has successfully removed the repeat expansion region and whether there are incompletely edited mixed clones. - Through single - molecule sequencing, researchers found that even after single - cell sorting, 20% - 80% of the edited clones are impure, indicating that even the best gene - editing practices need further verification. 3. **Quantifying different transcriptional variants of the C9orf72 gene**: - The C9orf72 gene can produce multiple different mRNA variants, of which the two main ones are variant 3 containing exon 1A and variant 2 containing exon 1B. Researchers designed ddPCR probes to specifically detect these two variants. - The experimental results show that in induced pluripotent stem cell (iPSC) - derived motor neurons, most C9orf72 mRNAs contain exon 1B, while mRNAs containing exon 1A account for only a small portion. In addition, knocking out exon 1A will significantly reduce the expression of exon 1B, while knocking out exon 1B has a smaller impact on the expression of exon 1A. 4. **Identifying and validating antibodies against dipeptide - repeat proteins (DPRs)**: - Repeat expansions of the C9orf72 gene can produce multiple dipeptide - repeat proteins (DPRs) through non - canonical translation, and these proteins may be toxic to cells. Therefore, identifying and validating specific DPR antibodies is crucial for studying the biological functions of these proteins. - Researchers tested 15 different antibody combinations and finally found two antibodies that specifically recognize poly - GA and poly - GP. These antibodies showed good specificity in patient iPSC - derived motor neurons, human post - mortem brain tissues, and transgenic mouse brain tissues. In summary, this paper aims to better understand the function of the C9orf72 gene and its pathological mechanisms in disease states by developing and validating a series of high - precision DNA, RNA, and protein detection methods. These methods are not only helpful for basic scientific research but also provide important tools for clinical trials.

Validated assays for the quantification of C9orf72 human pathology

Single-Molecule Sequencing of the C9orf72 Repeat Expansion in Patient iPSCs

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

Novel Clinical Associations with Specific C9ORF72 Transcripts in Patients with Repeat Expansions in C9ORF72.

Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs

Isoform Specific Antibodies Reveal Distinct Subcellular Localizations of C9orf72 in Amyotrophic Lateral Sclerosis.

CRISPR interference to evaluate modifiers of C9ORF72-mediated toxicity in FTD

Cerebellar C9ran Proteins Associate with Clinical and Neuropathological Characteristics of C9ORF72 Repeat Expansion Carriers

Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers

Abundant transcriptomic alterations in the human cerebellum of patients with a C9orf72 repeat expansion

Unaffected mosaic C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression.

Targeted Degradation of Sense and Antisense C9orf72 RNA Foci As Therapy for ALS and Frontotemporal Degeneration

A robust evaluation of TDP-43, poly GP, cellular pathology, and behavior in a AAV-C9ORF72 (G4C2)66 mouse model

Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids

Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons

Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36

Comprehensive Preclinical Evaluation of Human-Derived Anti-Poly-ga Antibodies in Cellular and Animal Models of C9ORF72 Disease

C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels

C9orf72 gene networks in the human brain correlate with cortical thickness in C9-FTD and implicate vulnerable cell types

Reversal of C9orf72 mutation-induced transcriptional dysregulation and pathology in cultured human neurons by allele-specific excision

Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide